This means that the vaccine candidate is screened on an ongoing basis, with MHRA accepting and verifying new evidence as soon as it becomes available. “The most critical factor has been the need to obtain adequate doses of safe and effective vaccines against COVID-19 as soon as possible to save lives,” Baldassarre wrote in an email to NPR. “We have been able to do this while ensuring that the American public pays a reasonable price for the production and delivery of this vaccine, which has sufficiently identified and preserved the U.S. government`s appropriate intellectual property rights.” Eighty higher-income economies, which would fund vaccines from their own public budgets, have so far submitted expressions of interest to confirm their intention to participate before the August 31 deadline. They will work with 92 low- and middle-income countries that will be supported by the CMA when it reaches its funding targets. Together, this group of 172 countries represents more than 70% of the world`s population. This group includes representatives from all continents and more than half of the G20 economies. Standardization of vaccines against coronavirus diseases (COVID-19) “Until all necessary levels are completed and a vaccine for use by the drug regulator, MHRA, be authorized, the public must continue to take the necessary steps to keep themselves and their loved ones safe, including compliance with hand, face, space and other public health recommendations, in accordance with the area in which they live,” the government said in a statement yesterday. After the European Medicines Agency (EMA) receives the marketing authorisation, doses of the BNT162b2 vaccine are ordered by EU Member States. COVAX`s goal is to provide by the end of 2021 two billion doses of safe and effective vaccines that have passed WHO approval and/or prequalification.
These vaccines are offered in the same way to all participating countries, in equal proportions to their population, first giving priority to health-related safety agents and then extending them to vulnerable groups such as the elderly and people with pre-existing diseases. Further doses are then provided on the basis of the country`s needs, vulnerability and the COVID-19 threat. The COVAX facility will also retain a buffer of emergency doses and humanitarian use, including treating severe outbreaks before they become uncontrollable. Tedros Adhanom Ghebreyesus, head of the UN health agency, said at a briefing in Geneva on Monday that Covax was “the largest and largest portfolio of Covid vaccines in the world,” which prioritizes the most vulnerable people.